drugset / Trial / NCT01202227
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).
Timeline
- Start
- 2010-09
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pregabalin | Small molecule | 150 mg | — |
| Subject | Pregabalin | Small molecule | 600 mg | — |